
Charles River Laboratories statistics
$337.97−0.83%Close 13 Nov 2026 · Market value $16.06B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Charles River Laboratories is valued at $16.06B on its latest close. Its price is 399.6 times its earnings.
| Market value | $16.06B |
|---|
| Enterprise value | $18.88B |
|---|
| Price / earnings | 399.57 |
|---|
| Price / sales | 4.04 |
|---|
| Price / book | 4.98 |
|---|
| EV / EBITDA | 42.52 |
|---|
| EV / sales | 4.75 |
|---|
| Price / free cash flow | 40.18 |
|---|
| Price / free cash flow, own 5-year average | 27.34 |
|---|
| EV / EBIT | 117.67 |
|---|
| EV / free cash flow | 46.81 |
|---|
| Free cash flow yield | 2.5% |
|---|
Share price
| Latest close | $337.97 |
|---|
| Day's change | −0.8% |
|---|
| 52-week high | $379.63 |
|---|
| 52-week low | $146.20 |
|---|
| From 52-week high | −11.0% |
|---|
| Return · 1 month | +12.6% |
|---|
| Return · 3 months | +16.0% |
|---|
| Return · year to date | +69.4% |
|---|
| Return · 1 year | +97.1% |
|---|
| Beta · 1 year against the S&P 500 | 1.27 |
|---|
| 50-day average | $311.06 |
|---|
| 200-day average | $227.71 |
|---|
| RSI 14 | 52.5 |
|---|
| Average volume · 20 sessions | 1.3M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 33.0% |
|---|
| Operating margin | 0.6% |
|---|
| Net margin | −3.6% |
|---|
| Free cash flow margin | 12.9% |
|---|
| Return on equity | −4.4% |
|---|
| Return on assets | 0.3% |
|---|
| Return on invested capital | 0.3% |
|---|
| Return on invested capital, 5-year average | 5.5% |
|---|
| Return on capital employed | 0.4% |
|---|
| Stock-based compensation / revenue | 1.8% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $213.8M |
|---|
| Total debt | $2.63B |
|---|
| Net debt | $2.41B |
|---|
| Current ratio | 1.29 |
|---|
| Quick ratio | 0.86 |
|---|
| Debt / equity | 0.83 |
|---|
| Net debt / EBITDA | 5.64 |
|---|
| Interest coverage | 0.24 |
|---|
Growth
| Revenue, latest quarter on a year | −2.2% |
|---|
| Revenue, twelve months on a year | −1.2% |
|---|
| EPS, latest quarter on a year | +524% |
|---|
| Revenue, 5-year compound | +6.5% |
|---|
| Revenue, 10-year compound | +11.4% |
|---|
| Free cash flow, 5-year compound | +6.4% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 49.6M |
|---|
| Shares outstanding, 5-year compound | −0.4% |
|---|
| Net share repurchases | $360.0M |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $42.66M |
|---|
| Effective tax rate | −42.9% |
|---|
CRL in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.